IMMUNOCORE HOLDINGS PLC - AMERICAN DEPOSITARY SHAR

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

10 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

06 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

02 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

23 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

17 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

11 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

03 дек 2024 01:00:00 Источник Nasdaq GlobeNewswire

Immunocore to present at upcoming investor conferences

08 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore reports third quarter financial results and provides a business update

06 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

14 сен 2024 03:00:00 Источник Nasdaq GlobeNewswire

Immunocore to present at the 2024 Cantor Global Healthcare Conference

12 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire

Immunocore announces transition of Chief Financial Officer

29 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore reports second quarter financial results and provides a business update

08 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

01 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

18 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

01 июн 2024 07:59:59 Источник Nasdaq GlobeNewswire

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

31 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Immunocore to present at the Jefferies Global Healthcare Conference

30 май 2024 16:00:00 Источник Nasdaq GlobeNewswire

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

29 май 2024 07:00:00 Источник Nasdaq GlobeNewswire

Immunocore reports first quarter financial results and provides a business update

08 май 2024 07:00:00 Источник Nasdaq GlobeNewswire